If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
== United Kingdom == Below are the individuals appointed by Charles III in his right as King of the United Kingdom with honours within his own gift and with the advice of the Government for other honours.
Erin Shammel Baker is an American bioanalytical chemist specializing in developing ion mobility-mass spectrometry hybrid instruments for biological and environmental applications. Baker is an expert in the research of perfluoroalkyl and polyfluoroalkyl substances analysis.
Nagpur–Vijayawada Expressway is part of the Nagpur-Vijayawada Economic Corridor, which will connect Nagpur-Chandrapur (part greenfield) to Mancherial-Warangal (greenfield), Warangal-Khammam (greenfield), Khammam-Vijayawada (part greenfield). The tenders were issued in November 2022, and are likely to be completed by late 2024 or mid 2025. In Feb 2026 Feb, Maharashtra government approved Rs2,353cr to acquire land for Nagpur-Chandrapur section of this expressway. Raipur–Visakhapatnam Expressway will be an alternative to the Nagpur-Vijayawada Expressway for access to various ports across the Eastern Ghats in the Bay of Bengal. The Jalna-Nanded Expressway will also provide direct connectivity between the Vijayawada–Hyderabad Expressway (at Hyderabad) and the Mumbai–Nagpur Expressway (at Jalna). The Hyderabad–Indore Expressway through Akola via Nanded–Akola–Omkareshwar–Indore, which and will further connect to the Delhi–Mumbai Expressway via the Kota–Indore Expressway (136 km).
==== 10 Man Operational Ration Pack ==== The UK also fields a larger pack of rations intended to feed ten soldiers for 24 hours from centralised but basic preparation; generally similar in content to the single issue ORP but tending to contain larger quantities of food in cylindrical tin cans to be divided up on preparation, rather than individual retort pouches or packets. Even dry materials like sugar or biscuits are often packed in these cans. They contain ingredients for baking bread and tinned food, including vegetables, corned beef and sausages in lard. Also included are chocolate, pre-cooked chicken or beef in gravy and soya mince. Ten boxed one-man ORPs are supplied in larger boxes identical in shape to the single ten-man pack.
Sources: en.wikipedia.org
==== Multiple bodies per grave ==== Some couples or groups of people (such as a married couple or other family members) may wish to be buried in the same plot. In some cases, the coffins (or urns) may simply be buried side by side. In others, one casket may be interred above another. If this is planned for in advance, the first casket may be buried more deeply than is the usual practice so that the second casket may be placed over it without disturbing the first. In many states in Australia all graves are designated two or three depth (depending on the water table) for multiple burials, at the discretion of the burial rights holder, with each new interment atop the previous coffin separated by a thin layer of earth. As such all graves are dug to greater depth for the initial burial than the traditional six feet to facilitate this practice. Mass burial is the practice of burying multiple bodies in one location. Civilizations attempting genocide often employ mass burial for victims. However, mass burial may in many cases be the only practical means of dealing with an overwhelming number of human remains, such as those resulting from a natural disaster, an act of terrorism, an epidemic, or an accident. This practice has become less common in the developed world with the advent of genetic testing, but even in the 21st century remains which are unidentifiable by current methods may be buried in a mass grave. Individuals who are buried at the expense of the local authorities and buried in potter's fields may be buried in mass graves.
Diabetes mellitus is a metabolic disease that is characterized by chronic elevated blood glucose levels (hyperglycemia). Therefore, the main goal of diabetes management is to keep blood glucose levels within normal limits (or a diabetic target range) as often as possible. If diabetes is not well controlled, health challenges may develop. People with diabetes can measure blood glucose by various methods, such as with a glucose meter or a continuous glucose monitor, which monitors over several days. Long-term glucose levels (over 3 months) can also be measured by analysis of a blood sample. In addition to lifestyle modification, some individuals with type 2 diabetes may require medication to adequately control their blood glucose levels. Other goals of diabetes management are prevention or treatment of complications that can result from the disease itself and from its treatment.
The oldest known pills were made of the zinc carbonates hydrozincite and smithsonite. The pills were used for sore eyes and were found aboard the Roman ship Relitto del Pozzino, wrecked in 140 BC. The Berne zinc tablet is a votive plaque dating to Roman Gaul made of an alloy that is mostly zinc. The Charaka Samhita, thought to have been written between 300 and 500 AD, mentions a metal which, when oxidized, produces pushpanjan, thought to be zinc oxide. Zinc mines at Zawar, near Udaipur in India, have been active since the Mauryan period (c. 322 and 187 BC). The smelting of metallic zinc here, however, appears to have begun around the 12th century AD. One estimate is that this location produced an estimated million tonnes of metallic zinc and zinc oxide from the 12th to 16th centuries. Another estimate gives a total production of 60,000 tonnes of metallic zinc over this period. The Rasaratna Samuccaya, written in approximately the 13th century AD, mentions two types of zinc-containing ores: one used for metal extraction and another used for medicinal purposes.
The LE cell was discovered in bone marrow in 1948 by Hargraves et al. In 1957 Holborow et al. first demonstrated ANA using indirect immunofluorescence. This was the first indication that processes affecting the cell nucleus were responsible for SLE. In 1959 it was discovered that serum from individuals with SLE contained antibodies that precipitated with saline extracts of nuclei, known as extractable nuclear antigens (ENAs). This led to the characterisation of ENA antigens and their respective antibodies. Thus, anti-Sm and anti-RNP antibodies were discovered in 1966 and 1971, respectively. In the 1970s, the anti-Ro/anti-SS-A and anti-La/anti-SS-B antibodies were discovered. The Scl-70 antibody was known to be a specific antibody to scleroderma in 1979, however the antigen (topoisomerase-I) was not characterised until 1986. The Jo-1 antigen and antibody were characterised in 1980.
Railway transport in Malaysia is state-run, and spans some 2,783 kilometres (1,729 mi). As of 2016, Malaysia has the world's 26th-largest road network, with some 238,823 kilometres (148,398 mi) of roads. Malaysia's inland waterways are the world's 22nd-longest, and total 7,200 km (4,474 mi). Among Malaysia's 114 airports, the busiest one is Kuala Lumpur International Airport (KLIA), located in the Sepang District; it is also the 12th-busiest airport in Asia. Among the seven federal ports, the major one is Port Klang, which is the 13th-busiest container port. Malaysia's flag carrier is Malaysia Airlines, providing international and domestic air services. Malaysia's telecommunications network is second only to Singapore's in Southeast Asia, with 4.7 million fixed-line subscribers and more than 30 million cellular subscribers. There are 200 industrial parks along with specialised parks such as Technology Park Malaysia and Kulim Hi-Tech Park. Fresh water is available to over 95% of the population, with groundwater accounting for 90% of the freshwater resources. Although rural areas have been the focus of great development, they still lag behind areas such as the West Coast of Peninsular Malaysia. The telecommunication network, although strong in urban areas, is less available to the rural population. Malaysia's energy infrastructure sector is largely dominated by Tenaga Nasional, the largest electric utility company in Southeast Asia. Customers in Peninsular Malaysia are connected to electricity through the National Grid.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.